Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]
Antacids linked to reduced erlotinib efficacy

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show. [More]
XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]
Ramucirumab effective second-line option for NSCLC

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial. [More]
Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest. [More]
S-1 plus radiotherapy shows promise in elderly NSCLC patients

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found. [More]
Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and anatomic segmentectomy appear to offer similar perioperative and oncological outcomes in patients with stage I non-small-cell lung cancer, analysis suggests. [More]
Vaccine boosts advanced NSCLC patient survival

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy. [More]
Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma. [More]
Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery is a feasible treatment option for cancer patients with up to 10 brain metastases, Japanese researchers report in The Lancet Oncology. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Preoperative ultrasound reveals NSCLC chest wall invasion

Preoperative ultrasound reveals NSCLC chest wall invasion

Surgeon-performed ultrasound is a good alternative to computed tomography for the identification of chest wall invasion in patients with non-small-cell lung cancer, suggests research demonstrating 90% sensitivity for detection of the spread. [More]

Pre-op PET/CT predicts stage I NSCLC adjuvant chemotherapy benefit

Preoperative imaging could help guide the use of postoperative adjuvant chemotherapy in patients with early non-small-cell lung cancer, Japanese researchers believe. [More]
Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show. [More]
EGFR biomarkers predict NSCLC response to vandetanib

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel. [More]
CD157 important in malignant pleural mesothelioma

CD157 important in malignant pleural mesothelioma

CD157 plays a pivotal role in the progression of malignant pleural mesothelioma and may be useful in the stratification of patients into different prognostic groups, Italian research suggests. [More]

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate. [More]
Combined risk score enhances radiation pneumonitis prediction

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows. [More]
Standard TFI definition still applies for relapsed SCLC classification

Standard TFI definition still applies for relapsed SCLC classification

Italian researchers have confirmed that using a treatment-free interval cut-off of 60 days to classify relapsed small-cell lung cancer as sensitive or resistant can be regarded as the standard definition. [More]